Study to Gather Information About the Safety of Oral Anticoagulation Drugs and How Well These Drugs Work in Real World for Patients With Non-valvular Atrial Fibrillation (Irregularly Heart Beats Which is Not Caused by a Heart Valve Problem) (REATTAIN)

Bayer

Status: Completed

Conditions: Atrial Fibrillation

Treatments: Drug: Apixaban; Drug: Warfarin; Drug: Rivaroxaban (Xarelto); Drug: Dabigatran

Study type: Observational

Funder types: Industry

Identifiers

NCT04249401

20030

Details and patient eligibility

About

Oral anticoagulant (OAC) treatment with either vitamin K antagonists (VKAs) or non-vitamin K antagonist oral anticoagulants (NOACs) is essential in patients with atrial fibrillation for the prevention of stroke or systemic embolism (SE) a condition that happens when a blood clot forms elsewhere in the body and travels through the blood stream to plug another vessel. While there are significant number of real-world publications on the use and outcomes of NOACs for stroke prevention, evidence from routine clinical practice on the use and outcomes of reduced doses of NOACs is scarce. By evaluating routine clinical practice data from national registers in Denmark, Finland, Norway and Sweden, researchers want to gather information about the safety and how well reduced doses of NOACs work in patients with irregularly heartbeats which are not caused by a heart valve problem (non-valvular atrial fibrillation, NVAF). As a primary aim of this study, treatment with low doses of NOACs (Xarelto [generic name rivaroxaban], Eliquis [generic name apixaban] or Pradaxa [generic name dabigatran]) will be compared with VKAs (warfarin) in Nordic patients with NVAF to assess the occurrence of stroke and systemic embolism [effectiveness]) and intracranial hemorrhage a type of bleeding that occurs inside the skull [safety]).

Enrollment: 134,897 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with a qualifying oral OAC dispensed during the study period
• A primary diagnosis indicative of atrial fibrillation during the baseline period

Exclusion criteria

• Age < 18 years at index date
• Died on index date
• A diagnosis of valvular disease, pregnancy, transient cause of atrial fibrillation or venous thromboembolism in the baseline period or on the index date
• Hip or knee replacement surgery in the 60 days prior to or on the index date
• A dispensed prescription of heparin or fondaparinux in the 60 days prior to or on the index date
• A diagnosis of end-stage kidney disease or renal replacement therapy in the baseline period or on the index date
• More than one dispensed OAC (any dose of rivaroxaban, apixaban, dabigatran, edoxaban, or warfarin) on the index date
• A dispensed prescription of an OAC (any dose of rivaroxaban, apixaban, dabigatran, edoxaban, or warfarin) during the baseline period

Trial design

134,897 participants in 2 patient groups

Reduced dose NOAC

Description:

Participants with NVAF initiating treatment with reduced doses of individual non-vitamin K antagonist oral anticoagulants (NOACs)

Treatment:

Drug: Dabigatran

Drug: Rivaroxaban (Xarelto)

Drug: Apixaban

Vitamin K antagonists (VKA)

Description:

Participants with NVAF initiating treatment with vitamin K antagonists (VKA)

Treatment:

Drug: Warfarin